Valuation: Photocure ASA

Market Cap 1.51B 157M 138M 128M 118M 220M 15.06B 224M 1.52B 596M 7.42B 589M 576M 25.61B P/E 2026 *
16.8x
P/E 2027 * 35.3x
Enterprise Value 1.31B 136M 119M 111M 102M 190M 13.04B 194M 1.32B 516M 6.42B 510M 499M 22.18B EV / Sales 2026 *
1.99x
EV / Sales 2027 * 1.94x
Free-Float
94.52%
Yield 2026 *
-
Yield 2027 * -
1 day-2.75%
Current month-2.75%
1 month-2.75%
3 months-14.99%
6 months-14.14%
Current year-14.14%
1 month 6.01
Extreme 6.01
6.01
Current year 6.01
Extreme 6.01
7.39
1 year 5.58
Extreme 5.58
7.39
3 years 4.32
Extreme 4.32
7.39
5 years 4.21
Extreme 4.21
15.87
10 years 3
Extreme 3
17.57
Manager TitleAgeSince
Chief Executive Officer - 01/11/2018
Chief Tech/Sci/R&D Officer - 01/08/2021
Human Resources Officer - 01/02/2021
Director TitleAgeSince
Director/Board Member - 01/01/2022
Chairman - 27/09/2023
Director/Board Member - 23/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-2.75%0.00% - - 156M
+0.13%+1.56%+47.35%+164.01% 1,067B
+0.97%+5.10%+58.02%+53.98% 635B
-0.94%+0.95%+35.02%+81.05% 458B
+1.41%+7.75%+38.93%+32.88% 347B
+1.28%+2.82%+38.42%+43.21% 295B
+1.72%+2.33%+19.31%+20.79% 262B
+1.84%-1.03%-27.78%-38.45% 216B
+0.06%+2.72%+22.73%+59.97% 203B
+0.94%-2.80%+12.32%+69.09% 161B
Average +0.45%+1.33%+27.15%+54.06% 404.83B
Weighted average by Cap. +0.55%+1.95%+36.75%+79.84%

Financials

2026 *2027 *
Net sales 660M 68.43M 60.05M 55.81M 51.35M 95.78M 6.56B 97.64M 662M 260M 3.23B 256M 251M 11.16B 665M 68.95M 60.51M 56.24M 51.73M 96.51M 6.61B 98.38M 667M 262M 3.26B 258M 253M 11.24B
Net income 91.33M 9.47M 8.31M 7.73M 7.11M 13.26M 908M 13.52M 91.72M 35.94M 447M 35.51M 34.75M 1.55B 43.33M 4.5M 3.94M 3.67M 3.37M 6.29M 431M 6.41M 43.51M 17.05M 212M 16.85M 16.49M 733M
Net Debt -203M -21.02M -18.45M -17.15M -15.77M -29.43M -2.02B -30M -204M -79.75M -993M -78.79M -77.1M -3.43B -221M -22.96M -20.15M -18.73M -17.23M -32.14M -2.2B -32.76M -222M -87.1M -1.08B -86.05M -84.2M -3.74B
Logo Photocure ASA
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Employees
100
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
56.90NOK
Average target price
84.00NOK
Spread / Average Target
+47.63%

Quarterly revenue - Rate of surprise